Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/10/793   
Active ingredient: N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide
Indication: Treatment of Friedreich's ataxia
Sponsor: Repligen Europe Limited
25/28 North Wall Quay, Dublin 1, Dublin Co., Ireland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
06/10/2010 Orphan designation EMA/OD/026/10 (2010)6938 of 01/10/2010